We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Read MoreHide Full Article
Key Takeaways
{\"0\":\"Intellia reported a Q2 loss of $0.99 per share, beating estimates and improving from last year\'s $1.31 loss.\",\"1\":\"Q2 revenues rose to $14.2M on collaboration gains, surpassing estimates and doubling year over year.\",\"2\":\"Phase III studies for NTLA-2001 and NTLA-2002 are progressing, with key enrollment milestones on track.\"}
Intellia Therapeutics (NTLA - Free Report) reported second-quarter 2025 loss of 99 cents per share (including one-time expenses of change in fair value of investments), narrower than the Zacks Consensus Estimate of a loss of $1.03. In the year-ago quarter, the company had incurred a loss of $1.31 per share.
Intellia’s total revenues currently comprise only collaboration revenues. Intellia reported revenues of $14.2 million for the second quarter of 2025, beating the Zacks Consensus Estimate of $13 million. The figure increased significantly on a year-over-year basis, driven by cost reimbursements related to NTLA’s collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
Year to date, the stock has lost 1.7% compared with the industry’s decline of 1.2%.
Image Source: Zacks Investment Research
NTLA’s Q2 Earnings in Detail
Intellia’s collaboration revenues beat our model estimate of $7.9 million.
Research and development expenses totaled $97 million, down 15% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and other costs, partially offset by increased spending in pipeline activities.
General and administrative expenses decreased 14% year over year to $27.2 million, primarily due to a reduction in stock-based compensation expenses, partially offset by increased investments in establishing commercial infrastructure.
As of June 30, 2025, Intellia had cash, cash equivalents and marketable securities worth $630.5 million compared with $707.1 million as of March 31, 2025. The company expects this cash balance to fund its ongoing operations into the first half of 2027 and the anticipated first commercial launch.
NTLA's Recent Pipeline Updates
Intellia has collaborated with Regeneron for the development of its investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, also known as NTLA-2001), which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Nex-z is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits.
The phase III MAGNITUDE study is evaluating the safety and efficacy of nex-z in patients with ATTR-CM. Enrollment is currently ongoing in the study. During the reported quarter, Intellia suffered a major setback with nex-z development after it reported that a participant in the MAGNITUDE study experienced grade 4 liver transaminase elevations, indicating a notable increase in liver enzymes. Though the company noted that this adverse event appeared to have resolved without hospitalization or medical interference, it has raised concerns about the gene therapy’s safety in the long run.
Intellia dosed the first patient in the phase III MAGNITUDE 2 study evaluating nex-z for the treatment of patients with ATTRv-PN in April 2025. Enrollment in this study is expected to be completed by the first half of 2026.
Intellia is developing another pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema (HAE). NTLA completed enrolling HAE patients in the pivotal phase III HAELO study evaluating NTLA-2002 early and now expects to complete patient randomization during third-quarter 2025. Intellia dosed the first patient in the HAELO study in January 2025.
The company remains on track to submit a potential biologics license application for NTLA-2002 in HAE in the second half of 2026.
Intellia Therapeutics, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 33.5%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 8.2% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Key Takeaways
Intellia Therapeutics (NTLA - Free Report) reported second-quarter 2025 loss of 99 cents per share (including one-time expenses of change in fair value of investments), narrower than the Zacks Consensus Estimate of a loss of $1.03. In the year-ago quarter, the company had incurred a loss of $1.31 per share.
Intellia’s total revenues currently comprise only collaboration revenues. Intellia reported revenues of $14.2 million for the second quarter of 2025, beating the Zacks Consensus Estimate of $13 million. The figure increased significantly on a year-over-year basis, driven by cost reimbursements related to NTLA’s collaboration with Regeneron Pharmaceuticals (REGN - Free Report) .
Year to date, the stock has lost 1.7% compared with the industry’s decline of 1.2%.
Image Source: Zacks Investment Research
NTLA’s Q2 Earnings in Detail
Intellia’s collaboration revenues beat our model estimate of $7.9 million.
Research and development expenses totaled $97 million, down 15% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and other costs, partially offset by increased spending in pipeline activities.
General and administrative expenses decreased 14% year over year to $27.2 million, primarily due to a reduction in stock-based compensation expenses, partially offset by increased investments in establishing commercial infrastructure.
As of June 30, 2025, Intellia had cash, cash equivalents and marketable securities worth $630.5 million compared with $707.1 million as of March 31, 2025. The company expects this cash balance to fund its ongoing operations into the first half of 2027 and the anticipated first commercial launch.
NTLA's Recent Pipeline Updates
Intellia has collaborated with Regeneron for the development of its investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, also known as NTLA-2001), which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Nex-z is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits.
The phase III MAGNITUDE study is evaluating the safety and efficacy of nex-z in patients with ATTR-CM. Enrollment is currently ongoing in the study. During the reported quarter, Intellia suffered a major setback with nex-z development after it reported that a participant in the MAGNITUDE study experienced grade 4 liver transaminase elevations, indicating a notable increase in liver enzymes. Though the company noted that this adverse event appeared to have resolved without hospitalization or medical interference, it has raised concerns about the gene therapy’s safety in the long run.
Intellia dosed the first patient in the phase III MAGNITUDE 2 study evaluating nex-z for the treatment of patients with ATTRv-PN in April 2025. Enrollment in this study is expected to be completed by the first half of 2026.
Intellia is developing another pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema (HAE). NTLA completed enrolling HAE patients in the pivotal phase III HAELO study evaluating NTLA-2002 early and now expects to complete patient randomization during third-quarter 2025. Intellia dosed the first patient in the HAELO study in January 2025.
The company remains on track to submit a potential biologics license application for NTLA-2002 in HAE in the second half of 2026.
Intellia Therapeutics, Inc. Price, Consensus and EPS Surprise
Intellia Therapeutics, Inc. price-consensus-eps-surprise-chart | Intellia Therapeutics, Inc. Quote
NTLA’s Zacks Rank & Other Stocks to Consider
Intellia currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) and Immunocore (IMCR - Free Report) , carrying a Zacks Rank #2 each at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 33.5%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 8.2% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.